ANAHEIM, Calif., July 11, 2017 /PRNewswire/ — Volpara Solutions, Inc. will showcase its new Volpara®Enterprise™ DDP software, here at the AHRA's 45th Annual Meeting and Exposition, July 9-12, 2017. The VolparaEnterprise Clinical Applications software package offers access to VolparaDensity, VolparaDose and VolparaPressure, in a Software as a Service (SaaS) subscription model for the first time. Volpara Solutions will showcase its entire suite of quantitative breast imaging tools, which allow for personalized measurements of volumetric breast density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening, at AHRA (Booth #134).
VolparaEnterprise Clinical Applications provide quick, automated assessment of every mammography and tomosynthesis exam and produces a Volpara Scorecard for every patient with the following data:
• VolparaDensity, the most clinically validated 3D Density solution, is in use at sites across the globe helping radiologists assess breast density more objectively and helping them better consider who might benefit from additional screening. The volumetric Volpara Density Grades have been shown to correlate strongly to the sensitivity of mammography and have demonstrated a strong association with the risk of developing breast cancer.
• VolparaDose helps understand the X-ray dose delivered to the patient, based on her specific breast density. Unlike manufacturer dose, which is based on phantom measurements, VolparaDose is computed based on the patient's breast composition and provides a personalized dose measure because no two women are alike.
• VolparaPressure helps evaluate the effectiveness of the mammogram and to better understand the patient experience. The lack of consistent guidelines regarding mammographic compression has led to wide variation in its technical execution, as well as varying levels of discomfort or pain. VolparaPressure helps monitor and optimize pressure during mammography exams, which is important to decrease the discomfort experienced by women and to optimize screening outcomes.
VolparaEnterprise software, a Microsoft Azure-based solution, delivers key performance indicators (KPIs) for hundreds of performance and quality metrics, including patient positioning, compression and equipment utilization. The software provides continuous quality assurance and performance monitoring through dynamic, interactive dashboards. Updated with every mammography or tomosynthesis (3D mammography) exam, ConstantQuality™ metrics may help facilities comply with the FDA's new EQUIP inspection program.
Designed to support large or small enterprises, VolparaEnterprise software enables breast centers to perform rapid quality control checks that help optimize the productivity and efficiency of imaging resources. This in turn helps decrease costs through the reduction of retakes, increase employee effectiveness, and enhance the patient experience.
"Providing accurate automated measurements of volumetric breast density to help radiologists make better decisions about each patient's personalized screening needs, has always been one of Volpara's primary goals. We are proud that nearly 10 million women have had their breast density analyzed using VolparaDensity," said Ralph Highnam, PhD, Volpara Chief Scientist and CEO. "VolparaEnterprise software has seamlessly integrated with VolparaDensity to offer users a robust clinical management resource to optimize productivity, quality assurance and cancer detection rates. Leveraging this Microsoft Azure-based enterprise platform has led to a natural transition for VolparaDensity and our other clinical tools to a Software as a Service subscription model. We believe this will not only increase access to these critical breast imaging tools, but also expand their clinical utility."
About Volpara Solutions
Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand (formerly Matakina Technology). Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient-specific x-ray dose, breast compression, breast positioning and other factors designed to provide critical insight for breast imaging workflow. For more information, visit volparasolutions.com.